MELBOURNE, AUSTRALIA--(MARKET WIRE)--Jul 18, 2007 -- Living Cell Technologies Limited (ASX:LCT.AX - News), a leading developer of live cell therapy products to treat life threatening human diseases, announced today it is capitalizing on growing US investor interest in the Company through the establishment of a Level 1 American Depositary Receipt Program (ADR) sponsored by the Bank of New York.
